MX2024008055A - Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1. - Google Patents

Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1.

Info

Publication number
MX2024008055A
MX2024008055A MX2024008055A MX2024008055A MX2024008055A MX 2024008055 A MX2024008055 A MX 2024008055A MX 2024008055 A MX2024008055 A MX 2024008055A MX 2024008055 A MX2024008055 A MX 2024008055A MX 2024008055 A MX2024008055 A MX 2024008055A
Authority
MX
Mexico
Prior art keywords
methods
muc16
combination
ovarian cancer
antibodies
Prior art date
Application number
MX2024008055A
Other languages
English (en)
Spanish (es)
Inventor
Glenn Kroog
Min Zhu
Tracey Michelle Rowlands
Barcellos Goncalves Priscila Hermont
Thomas Smith Uldrick
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024008055A publication Critical patent/MX2024008055A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024008055A 2022-01-07 2023-01-06 Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1. MX2024008055A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263297333P 2022-01-07 2022-01-07
US202263342542P 2022-05-16 2022-05-16
US202263394483P 2022-08-02 2022-08-02
US202263421541P 2022-11-01 2022-11-01
PCT/US2023/010326 WO2023133280A1 (en) 2022-01-07 2023-01-06 Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
MX2024008055A true MX2024008055A (es) 2024-09-06

Family

ID=85199214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008055A MX2024008055A (es) 2022-01-07 2023-01-06 Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1.

Country Status (9)

Country Link
US (1) US20230312718A1 (https=)
EP (1) EP4460520A1 (https=)
JP (1) JP2025502061A (https=)
KR (1) KR20240130137A (https=)
AU (1) AU2023204751A1 (https=)
CA (1) CA3242629A1 (https=)
IL (1) IL313864A (https=)
MX (1) MX2024008055A (https=)
WO (1) WO2023133280A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194596A (en) * 2016-09-23 2022-12-06 Regeneron Pharma Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates
TW202542187A (zh) * 2023-12-12 2025-11-01 美商再生元醫藥公司 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
JP6240600B2 (ja) 2011-07-24 2017-11-29 キュアテク リミテッド ヒト化免疫モノクローナル抗体の変異体
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MY194596A (en) 2016-09-23 2022-12-06 Regeneron Pharma Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates
TW202504917A (zh) * 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法

Also Published As

Publication number Publication date
JP2025502061A (ja) 2025-01-24
CA3242629A1 (en) 2023-07-13
WO2023133280A1 (en) 2023-07-13
KR20240130137A (ko) 2024-08-28
EP4460520A1 (en) 2024-11-13
IL313864A (en) 2024-08-01
AU2023204751A1 (en) 2024-07-11
US20230312718A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
EP4424712A3 (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
CO2019012143A2 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CL2022002555A1 (es) Anticuerpos anti-ccr8 para el tratamiento del cáncer
MX2024008055A (es) Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1.
MX2024011298A (es) Métodos para tratar el sarcoma epitelioide recurrente con anticuerpos biespecíficos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1
MX2018007613A (es) Combinacion de anticuerpos anti proteina 1 de muerte celular (pd1) y anticuerpos anti grupo de diferenciacion 20 (cd20)/anti grupo de diferenciacion (cd3) biespecificos para tratar el cancer.
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
MX2024000780A (es) Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon.
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
JP2021533796A5 (https=)
BR112021020532A2 (pt) Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
WO2022174103A3 (en) Monoclonal antibodies specific for human ror1
ZA202309812B (en) Use of antibody in anti-tumor treatment
MX2021009533A (es) Composiciones y metodos para usar anticuerpos bispecificos para unirse al complemento y a un antigeno objetivo.
MX2024006187A (es) Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4.
MX2025001239A (es) Métodos para tratar cáncer de próstata resistente a la castración metastasico con anticuerpos biespecíficos anti-psma x anti-cd28 en combinación con anticuerpos anti-pd-1
MX2024014019A (es) Métodos para el tratamiento del cáncer de próstata resistente a la castración metastásico con anticuerpos biespecíficos anti-psma x anti-anticuerpos de cd3 solos o en combinación con anticuerpos anti-pd-1
MX2025010746A (es) Metodos de tratamiento del cancer con moleculas biespecificas anti-cd22 x anti-cd28
MX2024007456A (es) Manabodies dirigidos a antígenos tumorales p53 y métodos de uso.
TW202617776A (zh) 治療ｓｍａｒｃｂ１缺陷型癌症之方法
MX2026000164A (es) Anticuerpos pd-l1xcd28 biespecificos y metodos de uso de los mismos
MX2025010217A (es) Anticuerpos multiespecificos anti-cd3 y metodos de uso
MX2025006274A (es) Anticuerpos biespecíficos contra cd3 y cd20 caninas
MX2025000567A (es) Metodos para el tratamiento del cancer mediante el uso de anticuerpos anti-tigit
MX2025002390A (es) Metodos para el tratamiento del cancer utilizando anticuerpos anti- ctla4